The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other healt

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other healt

During this highly interactive session, panelists and experts representing policy makers, payers, providers, and patients will debate key challenges in iNHL management in light of recent health policy changes, new value-based models of care delivery, and unprecedented advances in targeted therapi

The goal of this activity is to increase participants’ ability to use immune checkpoint inhibitors for management of individual patients with urothelial cell and renal cell carcinoma to improve clinical outcomes and quality of life.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The purpose of this well-regarded program is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and other evidence-based treatment principles in the management of significant cancer types and supportive

The NCCN 2017 Oncology Nursing Program at the NCCN 22nd Annual Conference will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care.

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The treatment of breast cancer is rapidly evolving.